Citations

Clear

3314 citation(s) found for "Do, Alexander".

Association of rs613872 and Trinucleotide Repeat Expansion in the TCF4 Gene of German Patients With Fuchs Endothelial Corneal Dystrophy
Okumura, Naoki , Hayashi, Ryousuke, Nakano, Masakazu , Tashiro, Kei, Yoshii, Kengo, Aleff, Ross A., Butz, Malinda L., Highsmith, Edward W., Wieben, Eric D. , Fautsch, Michael P. , Baratz, Keith H. , Komori, Yuya, Ueda, Emi , Nakahara, Makiko , Weller, Julia M. , Tourtas, Theofilos , Schlötzer‐Schrehardt, Ursula , Kruse, Friedrich E., Koizumi, Noriko , Aleff, Ross, Butz, Malinda

Mayo Clinic

Cornea | April 9, 2019 | Volume: 38 | Issue: 7 | Pages: 799-805

10.1097/ico.0000000000001952 | PMID 30973406 Get It

Purpose: To investigate single nucleotide polymorphisms (SNPs) and trinucleotide repeat (TNR) expansion in the transcription factor 4 (TCF4) gene in a large cohort of German patients with Fuchs endothelial corneal dystrophy (FECD). Methods: Genomic DNA was obtained from 398 patients with FECD and from 58 non-FECD controls. Thirty-seven previously reported SNPs were evaluated by genotyping. The 398 FECD samples were analyzed for TNR expansions by short tandem repeat assays and Southern blotting. The possible associations between the TNR length and clinical parameters (age, sex, visual acuity, and central corneal thickness) were analyzed in 132 patients. Results: The SNPs in COL8A2, TCF8, LOXHD1, and AGBL1 showed no heterogeneity in 36 cases, although SLCA411 showed 3 nonsense mutations. SNPs were detected for TCF4 (rs613872, rs2123392, rs17089887, rs1452787, and rs1348047), but only rs613872 showed a significant association with FECD (P = 9.93 × 10−12). Overall, 315/398 (79%) patients harbored TNR lengths >50, whereas no non-FECD controls harbored TNR lengths >50. The TCF4 SNP rs613872 genotype was TT: 39 (67%), TG: 18 (31%), and GG: 1 (2%) in non-FECD controls; TT: 39 (47%), TG: 38 (46%), and GG: 6 (7%) in FECD cases harboring TNR <50; and TT: 23 (8%), TG: 224 (79%), and GG: 38 (13%) in FECD cases harboring TNR >50 (P = 2.93 × 10−25). No significant association was detected between the TNR length and clinical parameters. Conclusions: Our large German cohort demonstrated a significant association between the risk allele G in rs613872 and FECD, irrespective of TNR expansion, although this risk allele was more frequent in FECD cases with TNR expansion than without.
Brace Yourselves: Outcomes of Ponseti Casting and Foot Abduction Orthosis Bracing in Idiopathic Congenital Talipes Equinovarus
Kuzma, Alexander L. , Talwalkar, Vishwas, Muchow, Ryan D. , Iwinski, Henry J. , Milbrandt, Todd A. , Walker, Janet L. , Jacobs, Cale A.

Mayo Clinic

Journal of Pediatric Orthopaedics | April 9, 2019 | Volume: 40 | Issue: 1 | Pages: e25-e29

10.1097/bpo.0000000000001380 | PMID 30969199 Get It

Background: Foot abduction orthoses (FAO) are believed to decrease recurrence following treatment of congenital talipes equinovarus (CTEV) as described by Ponseti. The purpose of this project is to examine the outcomes of FAO bracing following treatment by the Ponseti method in a cohort of idiopathic CTEV patients. Methods: After IRB approval, a cohort of patients aged 3 to 46 days with idiopathic CTEV was identified in a previous prospective study of brace compliance by family report and sensor. Dimeglio score and family demographic information were collected. Initial treatment was by the Ponseti method, with or without Achilles tenotomy. Following correction, patients had three months of full-time FAO bracing during which parents kept a log of compliance. Patients were followed until recurrence (need for further treatment) or age 5. Results: In total, 42 patients with 64 affected feet met the above criteria and were included in the final analysis. Twenty-six feet (40%) went on to develop recurrence requiring further treatment, including casting, bracing, or surgery. Because of poor tolerance of the original FAO, 20 feet were transitioned to an alternative FAO, and 14 of these (70%) went on to recur (P<0.01). The casting duration (P=0.02) had a statistically significant relationship to recurrence. Patients who were casted for 9 weeks or more had a higher rate of recurrence (57.1% vs. 27.8%; P=0.02). Age at treatment start, Dimeglio score, demographic factors, and compliance during full-time bracing, whether by report or sensor, did not show a significant relationship with recurrence. Conclusions: The study showed a statistically significant relationship between the difficulty of CTEV correction and the risk of recurrent deformity requiring treatment. This relationship could be used to provide prognostic information for patients’ families. Caregiver-reported compliance was not significantly related to recurrence. Level of Evidence: Level III—Prognostic Retrospective Cohort Study.
Right ventricular and pulmonary vascular function indices for risk stratification of patients with pulmonary regurgitation
Egbe, Alexander C. , Miranda, William R. , Pellikka, Patricia A. , Pislaru, Sorin V. , Borlaug, Barry A. , Kothapalli, Srikanth, Ananthaneni, Sindhura, Najam, Maria , Abdelsamid, Mohamed Farouk, Connolly, Heidi M. , Sandhyavenu, Harigopal , Farouk Abdelsamid, Mohamed, Sabbah, Michael S. , Pellikka, Patricia A , Borlaug, Barry A

Mayo Clinic

Congenital Heart Disease | April 8, 2019 | Volume: 14 | Issue: 4 | Pages: 657-664

10.1111/chd.12768 | PMID 30957982 Get It

Optimum age for performing Fontan operation in patients with univentricular heart
Akintoye, Emmanuel , Veldtman, Gruschen , Miranda, William R. , Connolly, Heidi M. , Egbe, Alexander C. , Egbe, Alexander C.

Mayo Clinic

Congenital Heart Disease | April 4, 2019 | Volume: 14 | Issue: 2 | Pages: 138-139

10.1111/chd.12690 | PMID 30945806 Get It

Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline
Ismaila, Nofisat , Cheung, Matthew C. , Costello, Caitlin , Dhodapkar, Madhav V. , Kumar, Shaji , Lacy, Martha Q. , Lipe, Brea , Little, Richard F. , Nikonova, Anna S., Omel, James, Peswani, Namrata, Seth, Rahul , Vesole, David H. , Walker, Irwin , Whitley, Alexander C., Wildes, Tanya M. , Wong, Sandy W. , Martin, Tom, Lacy, Martha, Wildes, Tanya , Mıkhael, Joseph , Lipe, Brea , Nikonova, Anna, Prica, Anca A. , Raje, Noopur , Seth, Rahul

Mayo Clinic

Journal of Clinical Oncology | April 1, 2019 | Volume: 37 | Issue: 14 | Pages: 1228-1263

10.1200/jco.18.02096 | PMID 30932732 Get It

PURPOSE To provide evidence-based recommendations on the treatment of multiple myeloma to practicing physicians and others. METHODS ASCO and Cancer Care Ontario convened an Expert Panel of medical oncology, surgery, radiation oncology, and advocacy experts to conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and some phase II studies published from 2005 through 2018. Outcomes of interest included survival, progression-free survival, response rate, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS The literature search identified 124 relevant studies to inform the evidence base for this guideline. RECOMMENDATIONS Evidence-based recommendations were developed for patients with multiple myeloma who are transplantation eligible and those who are ineligible and for patients with relapsed or refractory disease.
238 Grumpy Old Men? The Association Between Age and Satisfaction in Men Undergoing Placement of Inflatable Penile Prostheses
Miller, Alexander T. , Ziegelmann, Matthew , Montgomery, Brian, Trost, Landon , Miller, A., Yang, David Y.

Mayo Clinic

The Journal of Sexual Medicine | March 29, 2019 | Volume: 16 | Issue: Supplement_1 | Pages: S115-S115

10.1016/j.jsxm.2019.01.245 Get It

269. GIANT CELL ARTERITIS WITH INTRACRANIAL VASCULITIS: A CASE SERIES
Hawkins, Alexander S., Crowson, Cynthia S. , Sánchez-Álvarez, Catalina , Koster, Matthew J. , Warrington, Kenneth J.

Mayo Clinic

Rheumatology | March 29, 2019 | Volume: 58 | Issue: Supplement_2 | Pages: No page available

10.1093/rheumatology/kez062.043 Get It

Cystic Fibrosis Transmembrane Conductance Regulator Genotype, Not Circulating Catecholamines, Influences Cardiovascular Function in Patients with Cystic Fibrosis
Bisch, Alexander L, Wheatley, Courtney M. , Baker, Sarah E. , Peitzman, Elizabeth R. , Iterson, Erik H. Van , Laguna, Theresa A. , Snyder, Eric M., Van Iterson, Erik H , Baker, Sarah E , Morgan, Wayne J.

Mayo Clinic

Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine | March 29, 2019 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/1179548419835788 | PMID 30956528 Get It

Background: Cystic fibrosis (CF) is a genetic disease affecting multiple organ systems of the body and is characterized by mutation in the gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR). Previous work has shown that a single dose of aβ-agonist increases cardiac output (Q) and stroke volume (SV) and decreases systemic vascular resistance (SVR) in healthy subjects. This effect is attenuated in patients with CF; however, the mechanism is unknown. Potential explanations for this decreased cardiovascular response to a β-agonist in CF include inherent cardiovascular deficits secondary to the CFTR mutation, receptor desensitization from prolonged β-agonist use as part of clinical care, or inhibited drug delivery to the bloodstream due to mucus buildup in the lungs. This study sought to determine the effects of endogenous epinephrine (EPI) and norepinephrine (NE) on cardiovascular function in CF and to evaluate the relationship between cardiovascular function and CFTR F508del mutation. Methods: A total of 19 patients with CF and 31 healthy control subjects completed an assessment of Q (C 2 H 2 rebreathing), SV (calculated from Q and heart rate [HR]), Q and SV indexed to body surface area (BSA, QI, and SVI, respectively), SVR (through assessment of Q and mean arterial blood pressure [MAP]), and HR (from 12-lead electrocardiogram [ECG]) at rest along with plasma measures of EPI and NE. We compared subjects by variables of cardiovascular function relative to EPI and NE, and also based on genetic variants of the F508del mutation (homozygous deletion for F508del, heterozygous deletion for F508del, or no deletion of F508del). Results: Cystic fibrosis patients demonstrated significantly lower BSA (CF = 1.71 ± 0.05 m 2 vs healthy = 1.84 ± 0.04 m 2 , P = .03) and SVI (CF = 30.6 ± 2.5 mL/beat/m 2 vs healthy = 39.9 ± 2.5 mL/beat/m 2 , P = .02) when compared with healthy subjects. Cystic fibrosis patients also demonstrated lower Q (CF = 4.58 ± 0.36 L/min vs healthy = 5.71 ± 0.32 L/min, P = .03) and SV (CF = 54 ± 5.5 mL/beat vs healthy = 73.3 ± 4.5 mL/beat, P = .01), and a higher HR (CF = 93.2 ± 3.9 bpm vs healthy = 80.5 ± 2.7 bpm, P < .01) and SVR (CF = 2082 ± 156 dynes*s/cm −5 vs healthy = 1616 ± 74 dynes*s/cm −5 , P = .01) compared with healthy subjects. Furthermore, CF patients demonstrated a lower SV ( P < .01) corrected for NE when compared with healthy subjects. No significant differences were seen in HR or Q relative to NE, or SVR relative to EPI. Differences were seen in SV (F (2,14) = 7.982, P < .01) and SV index (F (2,14) = 2.913, P = .08) when patients with CF were stratified according to F508del mutation (number of deletions). Conclusions: Individuals with CF have lower cardiac and peripheral hemodynamic function parameters at rest. Furthermore, these results suggest that impairment in cardiovascular function is likely the result of F508del CFTR genotype, rather than receptor desensitization or inhibited drug delivery.